A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "panleukemia" antigens
SUPPLEMENTARY MATERIALS
Supplementary Figure 1: HLA allotype-specific clustering analysis of "cancer-exclusive" HLA ligands on hematological cancers. A. "Cancer-exclusive" HLA-A*01:01 ligands identified on AML (light green, n=1), CML (dark green, n=4), CLL (red, n=4) and MM/MCL (orange/yellow, n=0/0) were analyzed by complete linkage clustering based on the Jaccard similarity coefficient. B. "Cancer-exclusive" HLA-A*03:01 ligands identified on AML (light green, n=5), CML (dark green, n=6), CLL (red, n=9) and MM/MCL (orange/yellow, n=2/2) were analyzed by complete linkage clustering based on the Jaccard similarity coefficient. C. "Cancer-exclusive" HLA-A*24:02 ligands identified on AML (light green, n=1), CML (dark green, n=1), CLL (red, n=3) and MM/MCL (orange/yellow, n=2/1) were analyzed by complete linkage clustering based on the Jaccard similarity coefficient. D. "Cancer-exclusive" HLA-B*07:02 ligands identified on AML (light green, n=1), CML (dark green, n=3), CLL (red, n=7) and MM/MCL (orange/yellow, n=3/2) were analyzed by complete linkage clusterin based on the Jaccard similarity coefficient. E. "Cancer-exclusive" HLA-B*08:01 ligands identified on AML (light green, n=2), CML (dark green, n=2), CLL (red, n=6) and MM/MCL (orange/yellow, n=0/0) were analyzed by complete linkage clustering based on the Jaccard similarity coefficient. F. "Cancer-exclusive" HLA-B*18:01 ligands identified on AML (light green, n=1), CML (dark green, n=2), CLL (red, n=2) and MM/MCL (orange/yellow, n=1/1) were analyzed by complete linkage clustering based on the Jaccard similarity coefficient. with the thickness of the edge positively correlating with the degree of similarity. A. Jaccard distance graph based on "cancer-exclusive" HLA-A*01:01 ligands identified on AML (light green, n=1), CML (dark green, n=4), CLL (red, n=4) and MM/MCL (orange/yellow, n=0/0). B. Jaccard distance graph based on "cancer-exclusive" HLA-A*03:01 ligands identified on AML (light green, n=5), CML (dark green, n=6), CLL (red, n=9) and MM/MCL (orange/yellow, n=2/2). C. Jaccard distance graph based on "cancer-exclusive" HLA-A*24:02 ligands identified on AML (light green, n=1), CML (dark green, n=1), CLL (red, n=3) and MM/MCL (orange/yellow, n=2/1). D. Jaccard distance graph based on "cancer-exclusive" HLA-B*07:02 ligands identified on AML (light green, n=1), CML (dark green, n=3), CLL (red, n=7) and MM/MCL (orange/yellow, n=3/2). E. Jaccard distance graph based on "cancer-exclusive" HLA-B*08:01 ligands identified on AML (light green, n=2), CML (dark green, n=2), CLL (red, n=6) and MM/MCL (orange/yellow, gn=0/0). F. Jaccard distance graph based on "cancer-exclusive" HLA-B*18:01 ligands identified on AML (light green, n=1), CML (dark green, n=2), CLL (red, n=2) and MM/MCL (orange/yellow, n=1/1). HLA-A*03:01 restricted "pan-leukemia" antigens identified across all four hematological malignancies. Peptides represented with frequencies ≥20% across all entities are marked in dark red, peptides represented with frequencies ≥20% across entities of the same lineage are marked in light red. A minimum value of n≥4 allotype positive samples was required for the calculation of presentation frequencies. HLA-B*07:02 restricted "pan-leukemia" antigens identified across all four hematological malignancies. Peptides represented with frequencies ≥20% across all entities are marked in dark red, peptides represented with frequencies ≥20% across entities of the same lineage are marked in light red. A minimum value of n≥4 allotype positive samples was required for the calculation of presentation frequencies.
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